贝利尤单抗在狼疮肾炎中的应用
Application of Belizumab in Lupus Nephritis
DOI: 10.12677/ACM.2023.1351179, PDF,   
作者: 孔 寒：青海大学临床医学院，青海 西宁；梅 峰：青海大学附属医院肾病科，青海 西宁
关键词: 贝利尤单抗；狼疮肾炎；系统性红斑狼疮；Belimumab； Lupus Nephritis； Systemic Lupus Erythematosus
摘要: 近十年来，狼疮性肾炎的发病率和患病率逐渐升高，使活动性狼疮肾炎患者达到肾脏完全缓解显得尤为重要。激素联合免疫抑制剂的治疗方案虽然可以达到较好的临床疗效，但长期应用激素所带来的不良反应也不少。而靶向B细胞治疗为狼疮性肾炎的治疗提供了新的方向，贝利尤单抗可以通过抑制B细胞活化因子来耗竭异常B细胞，从而达到治疗活动性狼疮肾炎的目的。国外已有大量临床数据可以表明贝利尤单抗的临床疗效和安全性。这种新型的治疗方案为改善自身免疫性肾病的患者的生活质量提供了可能，靶向B细胞治疗还包括许多其他的治疗，需要我们进一步了解研究。
Abstract: The incidence and prevalence of lupus nephritis have gradually increased in the last decade, and it is particularly important to enable patients with active lupus nephritis to achieve complete renal remission. Although hormone combined with immunosuppressive regimens can achieve better clinical efficacy, there are many adverse effects associated with long-term hormone application. Targeted B-cell therapy provides a new direction for the treatment of lupus nephritis. Belimumab can deplete abnormal B-cells by inhibiting B-cell activating factors, thus achieving the goal of treat-ing active lupus nephritis. A large amount of clinical data from abroad can demonstrate the clinical efficacy and safety of Belimumab. This novel treatment option offers the possibility to improve the quality of life of patients with autoimmune nephropathy. Targeted B-cell therapy also includes many other treatments that need to be further investigated for our understanding.
文章引用：孔寒, 梅峰. 贝利尤单抗在狼疮肾炎中的应用[J]. 临床医学进展, 2023, 13(5): 8421-8430. https://doi.org/10.12677/ACM.2023.1351179

参考文献

[1] Tian, J., Zhang, D., Yao, X., Huang, Y. and Lu, Q. (2023) Global Epidemiology of Systemic Lupus Erythematosus: A Comprehensive Systematic Analysis and Modelling Study. Annals of the Rheumatic Diseases, 82, 351-356. [Google Scholar] [CrossRef] [PubMed]
[2] Barber, M.R.W., Drenkard, C., Falasinnu, T., et al. (2021) Global Epidemiology of Systemic Lupus Erythematosus. Nature Reviews Rheumatology, 17, 515-532. [Google Scholar] [CrossRef] [PubMed]
[3] Stojan, G. and Petri, M. (2018) Epidemiology of Systemic Lupus Erythematosus: An Update. Current Opinion in Rheumatology, 30, 144-150. [Google Scholar] [CrossRef] 
[4] Jolly, M. (2005) How Does Quality of Life of Patients with Systemic Lupus Erythematosus Compare with That of Other Common Chronic Illnesses? The Journal of Rheumatology, 32, 1706-1708.
[5] Hanly, J.G., O’Keeffe, A.G., Su, L., et al. (2016) The Frequency and Outcome of Lupus Nephritis: Results from an International Inception Cohort Study. Rheumatology, 55, 252-262. [Google Scholar] [CrossRef] [PubMed]
[6] Jakes, R.W., Bae, S.C., Louthrenoo, W., et al. (2012) Systematic Review of the Epidemiology of Systemic Lupus Erythematosus in the Asia-Pacific Region: Prevalence, Incidence, Clini-cal Features, and Mortality. Arthritis Care & Research, 64, 159-168. [Google Scholar] [CrossRef] [PubMed]
[7] Tektonidou, M.G., Dasgupta, A. and Ward, M.M. (2016) Risk of End-Stage Renal Disease in Patients with Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis. Arthritis & Rheumatology, 68, 1432-1441. [Google Scholar] [CrossRef] [PubMed]
[8] Gasparotto, M., Gatto, M., Binda, V., Doria, A. and Moroni, G. (2020) Lu-pus Nephritis: Clinical Presentations and Outcomes in the 21st Century. Rheumatology, 59, v39-v51. [Google Scholar] [CrossRef] [PubMed]
[9] Almaani, S., Meara, A. and Rovin, B.H. (2017) Update on Lu-pus Nephritis. Clinical Journal of the American Society of Nephrology, 12, 825-835. [Google Scholar] [CrossRef] 
[10] Chen, Y.E., Korbet, S.M., Katz, R.S., Schwartz, M.M. and Lewis, E.J. (2008) Value of a Complete or Partial Remission in Severe Lupus Nephritis. Clinical Journal of the American Society of Nephrology, 3, 46-53. [Google Scholar] [CrossRef] 
[11] Fanouriakis, A., Kostopoulou, M., Cheema, K., et al. (2020) 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) Recommendations for the Management of Lupus Nephritis. Annals of the Rheumatic Diseases, 79, 713-723. [Google Scholar] [CrossRef] [PubMed]
[12] Rovin, B.H., Adler, S.G., Barratt, J., et al. (2021) Execu-tive Summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 100, 753-779. [Google Scholar] [CrossRef] [PubMed]
[13] 中华医学会风湿病学分会. 狼疮肾炎诊疗规范[J]. 中华内科杂志, 2021, 60(9): 784-790.
[14] Wang, Z., Wang, Y., Zhu, R., et al. (2015) Long-Term Survival and Death Causes of Systemic Lupus Erythematosus in China: A Systemic Review of Observational Studies. Medicine, 94, e794. [Google Scholar] [CrossRef] 
[15] Petri, M., Purvey, S., Fang, H. and Magder, L.S. (2012) Predictors of Organ Damage in Systemic Lupus Erythematosus: The Hopkins Lupus Cohort. Arthritis & Rheumatism, 64, 4021-4028. [Google Scholar] [CrossRef] [PubMed]
[16] Zahid, S., Mohamed, M.S., Wassif, H., et al. (2022) Analysis of Cardiovascular Complications during Delivery Admissions among Patients with Systemic Lupus Erythematosus, 2004-2019. JAMA Network Open, 5, e2243388. [Google Scholar] [CrossRef] [PubMed]
[17] Takada, K., Illei, G.G. and Boumpas, D.T. (2001) Cy-clophosphamide for the Treatment of Systemic Lupus Erythematosus. Lupus, 10, 154-161. [Google Scholar] [CrossRef] [PubMed]
[18] Bruni, C., Shirai, Y., Kuwana, M. and Matucci-Cerinic, M. (2019) Cyclophosphamide: Similarities and Differences in the Treatment of SSc and SLE. Lupus, 28, 571-574. [Google Scholar] [CrossRef] [PubMed]
[19] Chen, Y., Sun, J., Zou, K., Yang, Y. and Liu, G. (2017) Treat-ment for Lupus Nephritis: An Overview of Systematic Reviews and Meta-Analyses. Rheumatology International, 37, 1089-1099. [Google Scholar] [CrossRef] [PubMed]
[20] Tunnicliffe, D.J., Palmer, S.C., Henderson, L., et al. (2018) Immunosuppressive Treatment for Proliferative Lupus Nephritis. Cochrane Database of Systematic Reviews, No. 6, Article No. CD002922. [Google Scholar] [CrossRef] 
[21] Dooley, M.A., Jayne, D., Ginzler, E.M., et al. (2011) Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis. New England Journal of Medicine, 365, 1886-1895. [Google Scholar] [CrossRef] 
[22] Mok, C.C., Tong, K.H., To, C.H., Siu, Y.P. and Au, T.C. (2005) Tacrolimus for Induction Therapy of Diffuse Proliferative Lupus Nephritis: An Open-Labeled Pilot Study. Kidney International, 68, 813-817. [Google Scholar] [CrossRef] [PubMed]
[23] Zhou, T.B., Lin, S.J., Yang, S. and Lin, W.S. (2019) Effi-cacy and Safety of Tacrolimus in Induction Therapy of Patients with Lupus Nephritis. Drug Design, Development and Therapy, 13, 857-869. [Google Scholar] [CrossRef] 
[24] Liu, Z., Zhang, H., Liu, Z., et al. (2015) Multitarget Therapy for In-duction Treatment of Lupus Nephritis: A Randomized Trial. Annals of Internal Medicine, 162, 18-26. [Google Scholar] [CrossRef] 
[25] Zhang, H., Liu, Z., Zhou, M., et al. (2017) Multitarget Therapy for Mainte-nance Treatment of Lupus Nephritis. Journal of the American Society of Nephrology, 28, 3671-3678. [Google Scholar] [CrossRef] 
[26] Ayoub, I., Nelson, J. and Rovin, B.H. (2018) Induction Therapy for Lupus Nephritis: The Highlights. Current Rheumatology Reports, 20, Article No. 60. [Google Scholar] [CrossRef] [PubMed]
[27] 李鎛江, 肖友文, 董建华, 何玲, 潘红霞. 环磷酰胺联合激素诱导治疗狼疮性肾炎的临床效果[J]. 中外医学研究, 2020, 18(23): 28-30.
[28] Alforaih, N., Whittall-Garcia, L. and Touma, Z. (2022) A Review of Lupus Nephritis. The Journal of Applied Laboratory Medicine, 7, 1450-1467. [Google Scholar] [CrossRef] [PubMed]
[29] Marín-Rosales, M., Palafox-Sánchez, C.A., Franco-Topete, R.A., et al. (2023) Renal Tissue Expression of BAFF and BAFF Receptors Is Associated with Proliferative Lupus Nephritis. Jour-nal of Clinical Medicine, 12, Article No. 71. [Google Scholar] [CrossRef] [PubMed]
[30] Yap, D.Y.H. and Chan, T.M. (2019) B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis—Role in Pathogenesis and Effect of Immunosuppressive Treatments. Inter-national Journal of Molecular Sciences, 20, Article No. 6231. [Google Scholar] [CrossRef] [PubMed]
[31] Swaak, A.J.G., Huysen, V., Nossent, J.C. and Smeenk, R.J.T. (1990) Antinuclear Antibody Profiles in Relation to Specific Dis-ease Manifestations of Systemic Lupus Erythematosus. Clinical Rheumatology, 9, 82-95. [Google Scholar] [CrossRef] 
[32] Frodlund, M., Wetterö, J., Dahle, C., et al. (2020) Longitudinal An-ti-Nuclear Antibody (ANA) Seroconversion in Systemic Lupus Erythematosus: A Prospective Study of Swedish Cases with Recent-Onset Disease. Clinical & Experimental Immunology, 199, 245-254. [Google Scholar] [CrossRef] [PubMed]
[33] Enocsson, H., Sjöwall, C., Wirestam, L., et al. (2015) Four Anti-dsDNA Antibody Assays in Relation to Systemic Lupus Erythematosus Disease Specificity and Activity. The Journal of Rheu-matology, 42, 817-825. [Google Scholar] [CrossRef] [PubMed]
[34] Chan, O.T.M., Hannum, L.G., Haberman, A.M., Madaio, M.P. and Shlomchik, M.J. (1999) A Novel Mouse with B Cells but Lacking Serum Antibody Reveals an Antibody-independent Role for B Cells in Murine Lupus. The Journal of Experimental Medicine, 189, 1639-1648. [Google Scholar] [CrossRef] [PubMed]
[35] 张莹莹, 王世颖, 束庆, 等. 靶向B淋巴细胞治疗系统性红斑狼疮的生物制剂: 贝利尤单抗与泰它西普[J]. 中南药学, 2022, 20(10): 2356-2362.
[36] Anolik, J.H., Campbell, D., Felgar, R.E., et al. (2003) The Relationship of FcγRIIIa Genotype to Degree of B Cell Depletion by Rituximab in the Treatment of Systemic Lupus Erythematosus. Arthritis & Rheumatism, 48, 455-459. [Google Scholar] [CrossRef] [PubMed]
[37] Faustini, F., Sippl, N., Stålesen, R., et al. (2022) Rituximab in Systemic Lu-pus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Im-munogenicity. Frontiers in Immunology, 13, Article 826152. [Google Scholar] [CrossRef] [PubMed]
[38] Salazar-Camarena, D.C., Ortiz-Lazareno, P.C., Cruz, A., et al. (2016) Association of BAFF, APRIL Serum Levels, BAFF-R, TACI and BCMA Expression on Peripheral B-Cell Sub-sets with Clinical Manifestations in Systemic Lupus Erythematosus. Lupus, 25, 582-592. [Google Scholar] [CrossRef] [PubMed]
[39] Vital, E.M., Dass, S., Buch, M.H., et al. (2011) B Cell Bi-omarkers of Rituximab Responses in Systemic Lupus Erythematosus. Arthritis & Rheumatism, 63, 3038-3047. [Google Scholar] [CrossRef] [PubMed]
[40] Rönnblom, L. and Leonard, D. (2019) Interferon Pathway in SLE: One Key to Unlocking the Mystery of the Disease. Lupus Science & Medicine, 6, e000270. [Google Scholar] [CrossRef] [PubMed]
[41] Yazdany, J. and Davis, J. (2004) The Role of CD40 Ligand in Systemic Lupus Erythematosus. Lupus, 13, 377-380. [Google Scholar] [CrossRef] [PubMed]
[42] Comte, D., Karampetsou, M.P. and Tsokos, G.C. (2015) T Cells as a Therapeutic Target in SLE. Lupus, 24, 351-363. [Google Scholar] [CrossRef] [PubMed]
[43] Robles-Carrillo, L., Meyer, T., Hatfield, M., et al. (2010) An-ti-CD40L Immune Complexes Potently Activate Platelets In Vitro and Cause Thrombosis in FCGR2A Transgenic Mice. The Journal of Immunology, 185, 1577-1583. [Google Scholar] [CrossRef] [PubMed]
[44] Furie, R.A., Bruce, I.N., Dörner, T., et al. (2021) Phase 2, Ran-domized, Placebo-Controlled Trial of Dapirolizumab Pegol in Patients with Moderate-to-Severe Active Systemic Lupus Erythematosus. Rheumatology, 60, 5397-5407. [Google Scholar] [CrossRef] [PubMed]
[45] Jacobi, A.M., Mei, H., Hoyer, B.F., et al. (2010) HLA-DRhigh/CD27high Plasmablasts Indicate Active Disease in Patients with Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 69, 305-308. [Google Scholar] [CrossRef] [PubMed]
[46] Cole, S., Walsh, A., Yin, X., et al. (2018) Integrative Analysis Re-veals CD38 as a Therapeutic Target for Plasma Cell-Rich Pre-Disease and Established Rheumatoid Arthritis and System-ic Lupus Erythematosus. Arthritis Research & Therapy, 20, Article No. 85. [Google Scholar] [CrossRef] [PubMed]
[47] Bag-Ozbek, A. and Hui-Yuen, J.S. (2021) Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Therapeutics and Clinical Risk Management, 17, 39-54. [Google Scholar] [CrossRef] 
[48] Shrestha, S., Budhathoki, P., Adhikari, Y., et al. (2021) Belimumab in Lupus Nephritis: A Systematic Review and Meta-Analysis. Cureus, 13, e20440. [Google Scholar] [CrossRef] [PubMed]
[49] Parodis, I., Gatto, M. and Sjöwall, C. (2022) B Cells in Systemic Lupus Erythematosus: Targets of New Therapies and Surveillance Tools. Frontiers in Medicine, 9, Article 952304. [Google Scholar] [CrossRef] [PubMed]
[50] Vincent, F.B., Saulep-Easton, D., Figgett, W.A., Fairfax, K.A. and Mackay, F. (2013) The BAFF/APRIL System: Emerging Functions beyond B Cell Biology and Autoimmunity. Cytokine & Growth Factor Reviews, 24, 203-215. [Google Scholar] [CrossRef] [PubMed]
[51] Vincent, F.B., Kandane-Rathnayake, R., Koelmeyer, R., et al. (2019) Analysis of Serum B Cell-Activating Factor From the Tumor Necrosis Factor Family (BAFF) and Its Soluble Receptors in Systemic Lupus Erythematosus. Clinical & Translational Immunology, 8, e1047. [Google Scholar] [CrossRef] [PubMed]
[52] Schwarting, A., Relle, M., Meineck, M., et al. (2018) Renal Tubular Epithe-lial Cell-Derived BAFF Expression Mediates Kidney Damage and Correlates with Activity of Proliferative Lupus Ne-phritis in Mouse and Men. Lupus, 27, 243-256. [Google Scholar] [CrossRef] [PubMed]
[53] Furie, R., Rovin, B.H., Houssiau, F., et al. (2020) Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. New Eng-land Journal of Medicine, 383, 1117-1128. [Google Scholar] [CrossRef] 
[54] Navarra, S.V., Guzmán, R.M., Gallacher, A.E., et al. (2011) Efficacy and Safety of Belimumab in Patients with Active Systemic Lupus Erythe-matosus: A Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet, 377, 721-731. [Google Scholar] [CrossRef] 
[55] Furie, R., Petri, M., Zamani, O., et al. (2011) A Phase III, Randomized, Placebo-Controlled Study of Belimumab, a Monoclonal Antibody That Inhibits B Lymphocyte Stimulator, in Patients with Systemic Lupus Erythematosus. Arthritis & Rheumatism, 63, 3918-3930. [Google Scholar] [CrossRef] [PubMed]
[56] Stohl, W., Hiepe, F., Latinis, K.M., et al. (2012) Belimumab Reduces Auto-antibodies, Normalizes Low Complement Levels, and Reduces Select B Cell Populations in Patients with Systemic Lupus Erythematosus. Arthritis & Rheumatism, 64, 2328-2337. [Google Scholar] [CrossRef] [PubMed]
[57] Stohl, W., Schwarting, A., Okada, M., et al. (2017) Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythema-tosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Arthritis & Rheumatology, 69, 1016-1027. [Google Scholar] [CrossRef] [PubMed]
[58] Zhang, F., Bae, S.C., Bass, D., et al. (2018) A Pivotal Phase III, Randomised, Placebo-Controlled Study of Belimumab in Patients with Systemic Lupus Erythematosus Located in China, Japan and South Korea. Annals of the Rheumatic Diseases, 77, 355-363. [Google Scholar] [CrossRef] [PubMed]
[59] Li, M., Wang, Y., Zhao, J., et al. (2021) Chinese SLE Treatment and Research Group (CSTAR) Registry 2009-2019: Major Clinical Characteristics of Chinese Patients with Systemic Lupus Erythematosus. Rheumatology and Immunology Research, 2, 43-47. [Google Scholar] [CrossRef] [PubMed]
[60] Urowitz, M.B., Gladman, D.D., Ibanez, D., et al. (2012) Evolution of Disease Burden over Five Years in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis Care & Re-search, 64, 132-137. [Google Scholar] [CrossRef] [PubMed]
[61] Collins, C.E., Cortes-Hernández, J., Garcia, M.A., et al. (2020) Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies. Rheumatology and Therapy, 7, 949-965. [Google Scholar] [CrossRef] [PubMed]
[62] Urowitz, M.B., Ohsfeldt, R.L., Wielage, R.C., et al. (2019) Or-gan Damage in Patients Treated with Belimumab versus Standard of Care: A Propensity Score-Matched Comparative Analysis. Annals of the Rheumatic Diseases, 78, 372-379. [Google Scholar] [CrossRef] [PubMed]
[63] Bruce, I.N., Urowitz, M., Van Vollenhoven, R., et al. (2016) Long-Term Organ Damage Accrual and Safety in Patients with SLE Treated with Belimumab Plus Standard of Care. Lupus, 25, 699-709. [Google Scholar] [CrossRef] [PubMed]
[64] Cassia, M., Alberici, F., Gallieni, M. and Jayne, D. (2017) Lupus Nephritis and B-Cell Targeting Therapy. Expert Review of Clinical Immunology, 13, 951-962. [Google Scholar] [CrossRef] 
[65] Atisha-Fregoso, Y., Malkiel, S., Harris, K.M., et al. (2021) Phase II Randomized Trial of Rituximab plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis & Rheumatology, 73, 121-131. [Google Scholar] [CrossRef] [PubMed]
[66] Cancro, M.P., D’Cruz, D.P. and Khamashta, M.A. (2009) The Role of B Lymphocyte Stimulator (BLyS) in Systemic Lupus Erythematosus. The Journal of Clinical Investigation, 119, 1066-1073. [Google Scholar] [CrossRef] 
[67] Samy, E., Wax, S., Huard, B., Hess, H. and Schneider, P. (2017) Targeting BAFF and APRIL in Systemic Lupus Erythematosus and Other Antibody-Associated Diseases. International Reviews of Immunology, 36, 3-19. [Google Scholar] [CrossRef] [PubMed]
[68] Steiger, S., Ehreiser, L., Anders, J. and Anders, H.-J. (2022) Biological Drugs for Systemic Lupus Erythematosus or Active Lupus Nephritis and Rates of Infectious Complications. Evidence from Large Clinical Trials. Frontiers in Immunology, 13, Article 999704. [Google Scholar] [CrossRef] [PubMed]

为你推荐